Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
59.86
+0.84 (1.42%)
At close: Oct 9, 2026, 4:00 PM EDT
60.62
+0.76 (1.27%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Exelixis Market Cap
Exelixis has a market cap or net worth of $14.83 billion as of October 9, 2026. It is the 1,541st most valuable company in the world and the 575th biggest in the United States. Its market cap has increased by 42.59% in one year.
Market Cap
14.83B
Enterprise Value
13.61B
1-Year Change
42.59%
Global Rank
Country Rank
#575 United States
Category
ChartMarket Cap Chart
Since April 17, 2000, Exelixis's market cap has increased from $630.80M to $14.83B, an increase of 2,251.33%. That is a compound annual growth rate of 12.66%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 14.83B | 26.22% |
| Dec 31, 2025 | 11.75B | 23.57% |
| Dec 31, 2024 | 9.51B | 27.47% |
| Dec 29, 2023 | 7.46B | 44.19% |
| Dec 30, 2022 | 5.17B | -10.54% |
| Dec 31, 2021 | 5.78B | -7.11% |
| Dec 31, 2020 | 6.23B | 16.30% |
| Dec 31, 2019 | 5.35B | -8.96% |
| Dec 31, 2018 | 5.88B | -34.61% |
| Dec 29, 2017 | 8.99B | 110.58% |
| Dec 30, 2016 | 4.27B | 233.29% |
| Dec 31, 2015 | 1.28B | 355.89% |
| Dec 31, 2014 | 281.10M | -75.11% |
| Dec 31, 2013 | 1.13B | 34.59% |
| Dec 31, 2012 | 839.00M | 36.62% |
| Dec 30, 2011 | 614.10M | -31.37% |
| Dec 31, 2010 | 894.80M | 13.07% |
| Dec 31, 2009 | 791.40M | 49.29% |
| Dec 31, 2008 | 530.10M | -41.23% |
| Dec 31, 2007 | 902.00M | 4.64% |
| Dec 29, 2006 | 862.00M | 10.08% |
| Dec 30, 2005 | 783.10M | 10.19% |
| Dec 31, 2004 | 710.70M | 41.83% |
| Dec 31, 2003 | 501.10M | 9.05% |
| Dec 31, 2002 | 459.50M | -44.16% |
View and export this data all the way back to 2000. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ascendis Pharma | 15.05B |
| Jazz Pharmaceuticals | 14.18B |
| Summit Therapeutics | 14.07B |
| Corcept Therapeutics | 13.10B |
| BridgeBio Pharma | 12.78B |
| Halozyme Therapeutics | 12.53B |
| Bio-Techne | 11.36B |
| ImmunityBio | 11.14B |